Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include…
The data center group looks very poor. $NBIX $CRWV $IREN etc
29 analysts rate NBIX Buy on consensus.
Consensus price target: $206.54 (+44.74% upside from $142.70)
| Insider | Date | Transaction | Shares | Value |
|---|---|---|---|---|
| BENEVICH ERIC Chief Commercial Officer | Sep 9, 2026 | Sale | 2,154 | $333.03K |
| Norwalk Leslie V director | Jul 28, 2026 | Sale | 1,250 | $227.51K |
| Delaet Ingrid Chief Regulatory Officer | Jul 9, 2026 | Sale | 8,433 | $1.51M |
| Delaet Ingrid Chief Regulatory Officer | Jul 8, 2026 | Sale | 2,737 | $488.67K |
| Delaet Ingrid Chief Regulatory Officer | Jul 7, 2026 | Sale | 3,401 | $607.31K |
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $2.86B | +21.45% | $478.6M |
| 2024 | $2.36B | +24.81% | $341.3M |
| 2023 | $1.89B | +26.76% | $249.7M |
Stock data for NBIX: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics